Status:

COMPLETED

Youth Smoking Cessation: Therapy +/- "The Patch"

Lead Sponsor:

University of California, Los Angeles

Collaborating Sponsors:

Philip Morris USA

Conditions:

Smoking

Eligibility:

All Genders

14-21 years

Phase:

NA

Brief Summary

Reducing tobacco use by adolescents is a national health priority. In recent polls, most adolescent smokers reported having tried unsuccessfully to quit. Smoking cessation treatment during adolescence...

Detailed Description

Tobacco use is the leading preventable cause of death in the United States, and current estimates project that 6.4 million of our nation's youth will die prematurely from a smoking-related disease (Fe...

Eligibility Criteria

Inclusion

  • Participants must meet all of the following inclusion criteria:
  • age of 14-21 years, inclusive
  • regular cigarette smoking at least five times a day in the month before entry into the study and initiation of smoking at least 6 months before entry
  • A score of 35 or greater on the Cigarette Dependence Scale-12
  • youth provide informed assent (for youth \<18 yr) or consent (for youth ≥18 yr) and parents provide informed consent to participate in the project
  • documented approval to participate from the participant's treating physician for participants currently receiving treatment for a serious medical or psychiatric condition
  • current contact information (address, telephone number), which is needed for follow-up
  • able to complete study assessments and participate in the intervention (e.g., lives \< 1 hr. away from the site, has family to participate in the intervention, does not have mental retardation)
  • youth or primary caregivers speak English or Spanish

Exclusion

  • Participants must meet none of the following exclusion criteria in order to be eligible to receive optional nicotine replacement:
  • smoke less than 5 cigarettes per day
  • have serious cardiovascular disease, including uncontrolled hypertension, coronary artery disease, serious cardiac arrhythmias, vasospastic disease, or angina, due to potential cardiovascular effects of nicotine, as determined via the baseline medical history and physical exam
  • have a medical condition that could be made worse by treatment with nicotine, including poorly controlled insulin dependent diabetes, uncontrolled hyperthyroidism, pheochromocytoma, severe oropharyngeal, esophageal, or peptic ulcer disease, or severe renal or hepatic impairment as determined via the baseline medical history and physical exam
  • have an allergy to adhesive tape or latex or serious dermatologic disease (excluding minor skin conditions such as mild eczema) due to potential for skin allergy to patch
  • have a known allergy to nicotine or any component of the nicotine patches
  • be receiving treatment with adenosine or bupropion due to potential drug-drug interactions
  • be pregnant or sexually active and not using reliable birth control methods consistently (for females)

Key Trial Info

Start Date :

December 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2009

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT00631020

Start Date

December 1 2007

End Date

October 1 2009

Last Update

April 22 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UCLA

Los Angeles, California, United States, 90095